Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Moser

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Journal of Gastrointestinal Cancer|March 29, 2021
Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province ExperienceTayyaba Bhatti, Michael Moser, Kiat Tsong Tan, et al.
The Journal of Organic Chemistry|April 9, 2010
Chemoenzymatic synthesis of Amaryllidaceae constituents and biological evaluation of their C-1 analogues. The next generation synthesis of 7-deoxypancratistatin and trans-dihydrolycoricidineJonathan Collins, Uwe Rinner, Michael Moser, et al.
Cellular & Molecular Immunology|November 24, 2018
TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasisAizhang Xu, Lifeng Zhang, Jingying Yuan, et al.
Sports Medicine (Auckland, N.Z.)|August 22, 2016
Concussion May Increase the Risk of Subsequent Lower Extremity Musculoskeletal Injury in Collegiate AthletesDaniel C Herman, Debi Jones, Ashley Harrison, et al.
Biochemical and Biophysical Research Communications|June 15, 2012
Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progressionAlejandro S Godoy, Paula C Sotomayor, Marcelo Villagran, et al.
Journal of Translational Medicine|June 24, 2026
Implementing informed consent in federated medical research: a blueprint designed to safeguard data subject rights in GermanyChristopher Hampf, Astrid Wiebke Pley, Peter Penndorf, et al.
Pancreas|January 6, 2023
Early Single-Center Experience With Irreversible Electroporation for Stage 2, 3, and 4 Pancreatic AdenocarcinomasChris Wall, Shahid Ahmed, Rasel Kabir, et al.
Cancer Immunology, Immunotherapy : CII|November 18, 2025
CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8<sup>+</sup>CD103<sup>+</sup> cDC1 and TRM cell responsesZhaojia Wu, Zhenyu Yang, Tauqeer Iftikhar, et al.
Biochemistry|February 16, 2007
The entire N-terminal half of TatC is involved in twin-arginine precursor bindingEva Holzapfel, Gottfried Eisner, Meriem Alami, et al.
Cellular & Molecular Immunology|November 16, 2021
Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumorsFatma Babikr, Jiangbo Wan, Aizhang Xu, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Journal of Gastrointestinal Cancer|March 29, 2021
Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province ExperienceTayyaba Bhatti, Michael Moser, Kiat Tsong Tan, et al.
The Journal of Organic Chemistry|April 9, 2010
Chemoenzymatic synthesis of Amaryllidaceae constituents and biological evaluation of their C-1 analogues. The next generation synthesis of 7-deoxypancratistatin and trans-dihydrolycoricidineJonathan Collins, Uwe Rinner, Michael Moser, et al.
Cellular & Molecular Immunology|November 24, 2018
TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasisAizhang Xu, Lifeng Zhang, Jingying Yuan, et al.
Sports Medicine (Auckland, N.Z.)|August 22, 2016
Concussion May Increase the Risk of Subsequent Lower Extremity Musculoskeletal Injury in Collegiate AthletesDaniel C Herman, Debi Jones, Ashley Harrison, et al.
Biochemical and Biophysical Research Communications|June 15, 2012
Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progressionAlejandro S Godoy, Paula C Sotomayor, Marcelo Villagran, et al.
Journal of Translational Medicine|June 24, 2026
Implementing informed consent in federated medical research: a blueprint designed to safeguard data subject rights in GermanyChristopher Hampf, Astrid Wiebke Pley, Peter Penndorf, et al.
Pancreas|January 6, 2023
Early Single-Center Experience With Irreversible Electroporation for Stage 2, 3, and 4 Pancreatic AdenocarcinomasChris Wall, Shahid Ahmed, Rasel Kabir, et al.
Cancer Immunology, Immunotherapy : CII|November 18, 2025
CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8<sup>+</sup>CD103<sup>+</sup> cDC1 and TRM cell responsesZhaojia Wu, Zhenyu Yang, Tauqeer Iftikhar, et al.
Biochemistry|February 16, 2007
The entire N-terminal half of TatC is involved in twin-arginine precursor bindingEva Holzapfel, Gottfried Eisner, Meriem Alami, et al.
Cellular & Molecular Immunology|November 16, 2021
Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumorsFatma Babikr, Jiangbo Wan, Aizhang Xu, et al.
Pageof 8